title: Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis.
abstract: The efficacy of cidofovir in juvenile recurrent respiratory papillomatosis (JRRP) remains uncertain due to the lack of published case-control studies.
  
  
  OBJECTIVE
  To establish factors affecting the progression of JRRP prognosis, and to evaluate cidofovir for eradicating JRRP.
  
  
  METHODS
  Retrospective.
  
  
  METHODS
  22 children with JRRP were evaluated at a referral center. All children underwent surgical debulking, followed by cidofovir injection (Group 2) or not (Group 1). Age at diagnosis was correlated with the Derkay score and disease outcome. Disease progression was compared between groups 1 and 2.
  
  
  RESULTS
  fifteen children were considered disease-free; 8 were in Group 2 and 7 in Group 1. Age and total and clinical scores (P<0.05) were negatively correlated. The mean number of surgeries required to control the disease was identical in both groups; the duration of treatment until remission was significantly higher in Group 1 (P<0,05).
  
  
  CONCLUSIONS
  JRRP is more aggressive in earlier onset disease. The duration of treatment was significantly lower in patients treated with cidofovir until eradication of JRRP compared to patients treated with surgery only.
authors.affiliation: FMRP, USP, Brazil.
authors.forename: Fabiana
authors.initials: F
authors.lastname: Valera
authors.forename: Lucas
authors.initials: L
authors.lastname: Maldonato
authors.forename: Jessé
authors.initials: J
authors.lastname: Lima
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Küpper
authors.forename: Rodrigo N
authors.initials: RN
authors.lastname: Lacerda
authors.forename: Rui
authors.initials: R
authors.lastname: Mamede
authors.forename: Hilton
authors.initials: H
authors.lastname: Ricz
mesh_terms: D000367:Age Factors; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000628:therapy*; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000628:therapy*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir